Search Articles — Sudonull

Search Results

From other projects

Cholesterol gene therapy VERVE-102: NEJM data, LDL reduction by 62%

https://ymaho.com/cholesterol-gene-therapy-verve-102-nejm-data-ldl-reduction-by-62

NEJM published phase 1b results of gene therapy VERVE-102: LDL reduction by 62% after a single injection. Analysis of efficacy, risks, and prospects for patients with hypercholesterolemia. Read more.

CRISPR in vivo reduces cholesterol by 60% in VERVE-102 study

https://ymaho.com/crispr-in-vivo-reduces-cholesterol-by-60-in-verve-102-study

Single infusion of VERVE-201 sustainably lowers LDL by more than 60%. Learn how CRISPR editing is changing the hypercholesterolemia therapy market. Read the analysis.

CRISPR therapy VERVE-102 reduces cholesterol by 62% after injection

https://ymaho.com/crispr-therapy-verve-102-reduces-cholesterol-by-62-after-injection

Journal NEJM published data on the drug VERVE-102: a single CRISPR injection (base editing) reduces LDL by 62% for 18 months without serious side effects. Learn details about the revolutionary therapy.

Trending Now